SCHEMBL30689299

SCHEMBL30689299

O=C(O)C(Cc1nc(-c2ccc(Oc3ccc(C(F)(F)F)cn3)cc2)no1)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 1/20 0.51
▸ SCN9A Q15858 11/20 0.51
▸ LMNA P02545 1/20 0.50
▸ LTA4H P09960 1/20 0.49
▸ RAB9A P51151 1/20 0.47
▸ FPR2 P25090 1/20 0.47
▸ MAPT P10636 2/20 0.45
▸ PKM P14618 1/20 0.45
▸ XBP1 P17861 1/20 0.45
▸ TP53 P04637 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ LIPE Q05469 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30689380 0.91 LMNA (0.54) FFAR1SCN9ALMNALTA4HFPR2
SCHEMBL27204771 0.86 SCN9A (0.50) FFAR1SCN9ALMNALTA4HRAB9A
SCHEMBL27171425 0.86 SCN9A (0.50) FFAR1SCN9ALMNALTA4HRAB9A
SCHEMBL27204647 0.85 LTA4H (0.67) FFAR1SCN9ALMNALTA4HFPR2
SCHEMBL27171402 0.85 LTA4H (0.67) FFAR1SCN9ALMNALTA4HFPR2
SCHEMBL30731680 0.85 SCN9A (0.53) FFAR1SCN9ALMNALTA4HFPR2
SCHEMBL30005275 0.85 LTA4H (0.52) FFAR1SCN9ALMNALTA4HFPR2
SCHEMBL27171409 0.84 LMNA (0.46) FFAR1SCN9ALMNALTA4HFPR2
SCHEMBL27204662 0.84 LMNA (0.46) FFAR1SCN9ALMNALTA4HFPR2
SCHEMBL30689302 0.84 FFAR1 (0.49) FFAR1SCN9ALMNARAB9AFPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4543875-A1 OXADIAZOLE DERIVATIVES, PREPARATION PROCESS THEREOF AND THEIR USE IN TREATING INFLAMMATORY DISEASES Sitryx Therapeutics Limited (GB) 2025-04-30 — — EP disclosed
WO-2023247958-A1 OXADIAZOLE DERIVATIVES, PREPARATION PROCESS THEREOF AND THEIR USE IN TREATING INFLAMMATORY DISEASES SITRYX THERAPEUTICS LIMITED (GB) 2023-12-28 — — WO disclosed
Send feedback